Twenty patients with CRPS type I ( n = @ ) and II of the upper limb and abnormally low PPT were double-blind randomised into @ groups of @ patients each to receive a @-day intravenous treatment of either @ mg parecoxib per day ( group I ) or placebo ( NaCl @ % , group II ) .